Outcomes and characteristics of non-melanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Laing, Heather; Garg, Mamta; Wadelin, Frances

Author

Laing, Heather
Garg, Mamta
Wadelin, Frances

Keyword

Non-melanoma skin cancers
ruxolitinib
MPN patients

Date

2023-11-14

Abstract

Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

Citation

Rampotas, A., Carter-Brzezinski, L., Somervaille, T. C., Forryan, J., Panitsas, F. P., Harrison, C. N., Witherall, R., Innes, A. J., Wallis, L., Butt, N. M., Psaila, B., Mead, A. J., Carter, M., Godfrey, A. L., Laing, H., Garg, M., Francis, S., Ewing, J., Teh, C. H., Cowan, H. B., … Lambert, J. (2023). Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib. Blood, blood.2023022345. Advance online publication. https://doi.org/10.1182/blood.2023022345